Ultragenyx Pharmaceutical

RARE

Market cap $3.22B

RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.

Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Maxwell Skor - Morgan Stanley, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Will Soghikian - Leerink Partners LLC, Research Division Joyce Chang Robbins - JPMorgan Chase & Co, Research Division Steve Scala - TD Cowen, Research Division Mehdi Goudarzi - Truist Securities, Inc., Research Division Mitchell Kapoor - H.C.

The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ultragenyx (RARE) came out with a quarterly loss of $1.81 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.4 per share a year ago.

Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price Proceeds to fund four expected launches, setting the company up for the next stage of growth NOVATO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the sale, for $400 million, of an additional 25% of the company's royalty interest from Kyowa Kirin Co., Ltd on the future sales of Crysvita® (burosumab) in the United States (U.S.) and Canada to OMERS, one of Canada's largest defined benefit pension plans.

NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 4, 2025, to discuss its financial results and corporate update for the quarter ending September 30, 2025.

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 20,317 restricted stock units of the company's common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of October 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 62,232 shares of common stock of the company and 34,564 restricted stock units of the company's common stock to one newly hired non-executive officer employee of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 30, 2025, as an inducement material to the new employee entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company's business development, corporate development and alliance management functions.